- Home
- NVVE vs GLTO Comparison
NVVE vs GLTO Comparison
Compare NVVE & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- GLTO
- Stock Information
- Founded
- NVVE 1996
- GLTO 2011
- Country
- NVVE United States
- GLTO Denmark
- Employees
- NVVE N/A
- GLTO N/A
- Industry
- NVVE Oil Refining/Marketing
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- GLTO Health Care
- Exchange
- NVVE Nasdaq
- GLTO Nasdaq
- Market Cap
- NVVE 4.2M
- GLTO 4.5M
- IPO Year
- NVVE N/A
- GLTO 2020
- Fundamental
- Price
- NVVE $0.25
- GLTO $2.99
- Analyst Decision
- NVVE
- GLTO Buy
- Analyst Count
- NVVE 0
- GLTO 1
- Target Price
- NVVE N/A
- GLTO $10.00
- AVG Volume (30 Days)
- NVVE 5.1M
- GLTO 237.6K
- Earning Date
- NVVE 11-11-2025
- GLTO 10-31-2025
- Dividend Yield
- NVVE N/A
- GLTO N/A
- EPS Growth
- NVVE N/A
- GLTO N/A
- EPS
- NVVE N/A
- GLTO N/A
- Revenue
- NVVE $4,949,747.00
- GLTO N/A
- Revenue This Year
- NVVE $892.33
- GLTO N/A
- Revenue Next Year
- NVVE N/A
- GLTO N/A
- P/E Ratio
- NVVE N/A
- GLTO N/A
- Revenue Growth
- NVVE N/A
- GLTO N/A
- 52 Week Low
- NVVE $0.18
- GLTO $2.01
- 52 Week High
- NVVE $8.76
- GLTO $14.82
- Technical
- Relative Strength Index (RSI)
- NVVE 29.80
- GLTO 44.75
- Support Level
- NVVE $0.23
- GLTO $2.45
- Resistance Level
- NVVE $0.28
- GLTO $3.99
- Average True Range (ATR)
- NVVE 0.06
- GLTO 0.28
- MACD
- NVVE -0.00
- GLTO -0.02
- Stochastic Oscillator
- NVVE 23.13
- GLTO 34.74
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.